Rapid Influenza Diagnostic Tests Market Report | Demand & Trends 2030

[Research Report] The Rapid Influenza Diagnostic Tests Market Size is expected to grow from US$ 961.23 million in 2022 to US$ 2031.42 million by 2031; it is estimated to register a CAGR of 9.8% during the forecast period.

Market Insights and Analyst View:

Rapid influenza diagnostic test (RIDT) is used to detect influenza virus by detecting the presence of viral antigens in a patient’s respiratory secretions, such as nasal swabs, throat swabs, and others. Sometimes, these are also used in conjunction with other diagnostic tests, such as polymerase chain reaction, which are more accurate than RIDT and tables time in producing results. The constant evolution of the influenza virus has increased the prevalence of influenza among large populations. The advancement in existing technology of rapid test kits is also evolving to enhance the accuracy and reduce the false negative test. Moreover, high risk of transmission and low vaccination rates in developing and underdeveloped economies are also expected to drive the rapid influenza diagnostic test market in near future.

Growth Drivers and Challenges:

Influenza, commonly known as flu, is a highly contagious respiratory illness caused by influenza, which varies from year to year. It can be affected by various factors such as climate, population density and vaccination rates. In recent years the prevalence of influenza has increased globally. As per the article published in Forbes Health, ~9 million influenza cases were reported during 2021-2022 and caused 100,000 hospitalizations and 5,000 deaths in the US. Additionally, influenza virus is constantly evolving through a process known as antigenic drift which allows then to evade the immune system and cause new outbreaks. This makes the vaccinated population susceptible to the new virus strains.

Influenza can have a high risk of transmission through the cough and sneeze of an infected person, and it can survive up to 48 hours, increasing the transmission rate and contributing to the prevalence of influenza. Moreover, low vaccination rates in developing and underdeveloped economies owing to the lack of access, hesitancy, and misinformation led to the increasing prevalence of influenza. Therefore, high risk of transmission and low vaccination rates contribute to the increasing prevalence of influenza, which drives the growth of RIDT market.

However, the increasing use of molecular diagnostic tests such as polymerase chain reaction (PCR) tests are more sensitive, accurate, and reliable compared to RIDT. Molecular diagnostic tests can detect the range of influenza viruses with faster results. The increased risk of false negative results with RIDT can also delay the diagnosis and treatment, worsening the overall patient condition. Moreover, lack of standardization and regulation of RIDT can lead to the variation in test results, making it difficult for healthcare providers to make appropriate choice for their patients. 

Furthermore, high cost of RIDT compared to conventional laboratory-based test can affect the demand in developing and underdeveloped economies, making it unaffordable. Therefore, high cost, lack of standard regulations, increase in false negative results, and rising inclination towards molecular diagnostics are expected to hamper the growth of the RIDT market.

Strategic Insights

Report Segmentation and Scope:

The “Global Rapid Influenza Diagnostic Test Market Size” is segmented on the basis of test type, sample type, technology, end user and geography. Based on test type, the rapid influenza diagnostic test market is segmented into influenza A test, influenza B test, and influenza A+B test. Based on sample type, the rapid influenza diagnostic test market is segmented into nasal swab, throat swab and nasopharyngeal swab, and others. The rapid influenza diagnostic test market is segmented based on technology into immunochromatographic assays, immunofluorescence assays, and nucleic acid amplification test (NAAT). The rapid influenza diagnostic test market is segmented into hospitals and clinics, diagnostic centers, nursing homes, and others based on end user. The rapid influenza diagnostic test market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). 

Segmental Analysis:

Based on test type, the rapid influenza diagnostic test market size is segmented into influenza A, B, and influenza A+B tests. In 2022, the influenza A+B test segment held the largest market share and also expected to grow at the fastest rate during the coming years owing to the advantages associated with influenza A+B test such as quick diagnosis and ease of use.

Rapid Influenza Diagnostic Test Market, by Sample Type – 2022 and 2031

Based on sample type, the rapid influenza diagnostic test market is segmented into nasal swab, throat swab, nasopharyngeal swab, and others. In 2022, the nasopharyngeal swab segment held the largest share of the market and expected to grow at the fastest rate during the coming years owing to the advantages offered by the nasopharyngeal swab includes higher yields and helps in quick diagnosis of influenza. This also helps in early diagnosis and treatment as compared to nasal or throat swab.

The rapid influenza diagnostic test market is segmented based on technology into immunochromatographic assays, immunofluorescence assays, and nucleic acid amplification test (NAAT). In 2022, the immunochromatographic assays segment held the largest share of the market and expected to grow at the fastest rate during the coming years owing to the excellent sensitivity and specificity along with applications. Moreover, various manufacturers are developing advanced immunochromatographic kits to diagnose various infections.

The rapid influenza diagnostic test market is segmented into hospitals and clinics, diagnostic centers, nursing homes, and others based on end user. In 2022, the hospitals and clinics segment held the largest share of the market. In addition, the diagnostic centers segment is also expected to grow at the fastest rate during the coming years. Hospitals and clinics experience the huge patient footfall as it provides all the healthcare facilities under one roof, making it a preferred choice for the large patient population.

Regional Analysis:

Based on geography, the rapid influenza diagnostic test market is categorized into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2022, North America held the largest rapid influenza diagnostic test market share, closely followed by Europe, and Asia Pacific is anticipated to register the highest CAGR during the forecast period. The increasing prevalence of influenza and surge influenza-related hospitalization in the region primarily drive the North American market growth. The US is expected to hold the major market share in North America region owing to the rising prevalence of influenza. According to CDC estimates, flu has led to 140,000 – 710,000 hospitalizations, 9 million – 41 million illnesses, and 12,000 – 52,000 deaths annually during 2010 and 2021. Moreover, the country houses some of the major manufacturers in the country that are focused on the development of advanced rapid influenza diagnostic tests, which led to the surge in product launches. For instance, in October 2021, Hologic launched the Aptima SARS-CoV-2/Flu Assay is, a multiplex COVID-19/flu test in North America and Europe for the detection of SARS-CoV-2, influenza A, and influenza B cause similar symptoms, including fever, cough, headache, and fatigue.  Furthermore, the increase in home healthcare led to the establishment of home-based influenza tests that are authorized by the U.S. Food and Drug Administration (FDA) in case of emergency. For instance, in 2023, The US FDA approved Lucira COVID-19 & Flu Home Test, the first over-the-counter (OTC) at-home diagnostic test for emergency use authorization (EUA) for the diagnosis of influenza A and B, which is commonly known as the flu.

However, Asia Pacific registered as the fastest-growing region in the global rapid influenza diagnostic test market. The market in this region is expected to increase significantly in countries such as China, Japan, and India. The market's growth is attributed to increasing focus of market players in developing economies, and supportive government policies. In addition, the developments of the companies, product launches, and the mergers and collaborations to form the better opportunities for the users and the manufacturers to the marketing and purchase. For instance, Kaneka Corporation has received authorization for the manufacturing and sale of “KANEKA Immunochromatography Flu A/B & SARS-CoV-2 Ag”, which can test for COVID-19 (SARS-CoV-2) and influenza virus antigens in a single sample collection.

Furthermore, the technological advances the rapid influenza diagnostic test and the increasing government funding are responsible for product launches and procedures in the healthcare sector. For instance, in April 2023, Molbio Diagnostics launched the Truenat H3N2/H1N1 for differential diagnosis of the H1N1 virus and H3N2. The Central Drugs Standard Control Organisation (CDSCO) has approved the test and can provide sample-to-result within an hour. Truenat H3N2/H1N1 is the first point-of-care real-time PCR test that aids in confirming influenza infections. Therefore, all the above factors are expected to drive the rapid influenza diagnostic test market growth.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global rapid influenza diagnostic test market are listed below:

1. In June 2023, Kaneka Corporation received authorization for the manufacturing and sale of “KANEKA Immunochromatography Flu A/B & SARS-CoV-2 Ag”, which can test for COVID-19 (SARS-CoV-2) and influenza virus antigens in a single sample collection.
2. In April 2023, Molbio Diagnostics launched the Truenat H3N2/H1N1 for differential diagnosis of the H1N1 virus and H3N2. The Central Drugs Standard Control Organisation (CDSCO) has approved the test and can provide sample-to-result within an hour. Truenat H3N2/H1N1 is the first point-of-care real-time PCR test that aids in confirming influenza infections.
3. In March 2023, Lucira Health, Inc. launched Lucira COVID-19 & Flu Home Test in the United States, as well as the combination test's inclusion in the Australian Register of Therapeutic Goods (ARTG) for healthcare professionals in a point-of-care setting. The COVID-19 & Flu Home Test is the first and only combination COVID-19 & Flu test to be granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for over-the-counter (OTC) use at home and other non-laboratory sites.
4. In January 2023, 2San launched a dual kit for SARS-CoV-2 & Influenza A+B. With the ongoing demand set upon the NHS post-pandemic, the over-the-counter kit has been launched to help alleviate pressures on healthcare institutions.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global rapid influenza diagnostic test market include Thermo Fisher Scientific Inc., Hologic, Abbott Laboratories, Siemens Helathineers AG, Quidel Corporation, Danaher Corporation, Meridian Bioscience, F. Hoffmann-La Roche, Becton Dickinson and company, and Luminex Corporation among others. These companies focus on geographical expansion and new product launches to meet global consumer demand and increase their product range in specialty portfolios. They have a widespread global presence, providing them with many customers and subsequently increasing their market share.

REGIONAL FRAMEWORK

Rapid Influenza Diagnostic Tests Market Report Analysis

MARKET PLAYERS

Rapid Influenza Diagnostic Tests Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.